RE:RE:RE:RE:RE:Key Takeaways From Stauffer and DanAnyone giving you a number for WOMAC pain relief estimates against placebo is a scam artist. There's no way to estimate that beforehand. Of course it's going to be
compared to Naproxen, just like it's going to be compared to Celebrex, non-selective NSAIDs and others, but that's not what the Phase 2 is designed to test.
Look man, you may think these are legitimate questions but you're clearly fearmongering. If anyone had these answers they wouldn't be doing clinical trials, they could skip to the end. But the whole point of clinical trials are to figure these questions out. That's not the company's fault for not knowing these things yet.
The point of AME was to de-risk Phase 3 so technically this was a good thing to do before running into failure with 150mg during Phase 3. So you're not going any points of superiority pointing these questions out on Stockhouse.
PlaySafe wrote: What is your confidence level that 75mg will be statistically signifigant to placebo over a two week period? And the WOMAC scores of the 75mg trial will be compared to the WOMAC scores of Naproxen so even though the Phase 2 doesn't compare Antibe's drug to Naproxen you can't get away with comparing the WOMAC with previous NSAID studies. Furthermore what is your confidence level of a 12 week phase 3 study and not seeing any anomolies in liver levels? In other words do you think that the Antibe scientists know exactly the long term impact of their molecule? If they did then they would have known to try lover doses during their Phase 2 trials and would have anticipated the AME issue.